MedTrace Logo

The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours.

NCT03275116 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-03-10

No results posted yet for this study

Summary

To study the effect of twice daily dual bronchodilation versus once daily single bronchodilation in patients with chronic obstructive pulmonary disease on 24-hour static and dynamic hyperinflation.

Conditions

  • Chronic Obstructive Airway Disease

Interventions

DRUG

Tiotropium 'Respimat' 5 mcg

Once daily single bronchodilation

DRUG

Aclidinium Bromide/Formoterol Fumarate 340/12 mcg

Twice daily dual bronchodilation

Sponsors & Collaborators

  • Center for Integrated Rehabilitation and Organ Failure Horn

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Lowie Vanfleteren, MD, PhD · CIRO, centre of expertise for chronic organ failure

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-07
Primary Completion
2020-04-30
Completion
2020-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03275116 on ClinicalTrials.gov